Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Quarterly Report · 10-Q

Kyverna Therapeutics, Inc.

KYTXNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 11, 2026Accepted Aug 11, 2026, 4:07 PM EDTCIK 1994702Accession 0001193125-26-344607
Share

Company context

Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently submitted Biologics License Application (BLA) for miv-cel in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG). Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data and significant unmet need, further reinforcing the therapy's potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit https://kyvernatx.com.

Current securities

Recent company filings

  1. 10-Q filingNov 12, 2026
  2. Results of Operations and Financial ConditionNov 12, 2026
  3. SCHEDULE 13G - filed by HIRSCHMAN ORIN regarding Kyverna Therapeutics, Inc.Oct 19, 2026
  4. Regulation FD DisclosureSep 24, 2026
  5. Results of Operations and Financial ConditionAug 11, 2026

Registered securities in this filing

Kyverna Therapeutics, Inc. · 10-Q · Filed 2026-08-11

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.00001 per share

Symbol
KYTX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_a91d1f67-5ac7-490f-9724-04a96db315e6

Dimensions: Not supplied

Accession 000119312526344607 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.